Kalytera Therapeutics, a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid (CBD) and synthetic CBD medicines, has appointed Jerome Zeldis, M.D., Ph.D., to its board of directors.
Zeldis serves as the chief medical officer of Celgene and also is the chief executive officer of Celgene Global Health, an organization whose mission is to develop and distribute therapeutics for diseases of the developing world. Prior to joining Celgene, Zeldis was associate director of clinical research at Sandoz Research Institute and director of medical development at Janssen Pharmaceutical Research Institute.
“Dr. Zeldis is a highly accomplished physician and pharmaceutical executive with an impressive track record of bringing important new drugs to market globally,” said Kalytera co-founder and board member David Stefansky.
Zeldis said, “I am intrigued with the potential of the preliminary work on CBD compounds that Kalytera and its research partners have achieved. I am pleased to contribute to the company’s mission of advancing CBD research to pioneer new pharmaceutical therapies for diseases affecting hundreds of millions of people worldwide.”